Response letter: "Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules"

. 2020 Sep 01 ; 16 (9) : 2282-2284. [epub] 20200818

Jazyk angličtina Země Spojené státy americké Médium print-electronic

Typ dokumentu dopisy, práce podpořená grantem, komentáře

Perzistentní odkaz   https://www.medvik.cz/link/pmid32810427
Komentář

PubMed

Komentář

PubMed

Zobrazit více v PubMed

Costantini M, Callegaro A, Beran J, Berlaimont V, Galgani I.. Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules. Hum Vaccin Immunother. 2020;1–6. doi:10.1080/21645515.2019.1700712. PubMed DOI PMC

Beran J, Lattanzi M, Xie F, Moraschini L, Galgani I.. Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10years antibody persistence. Vaccine. 2019;37(32):4623–29. doi:10.1016/j.vaccine.2017.12.081. PubMed DOI

Beran J, Xie F, Zent O. Five year follow-up after a first booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates long-term antibody persistence and safety. Vaccine. 2014;32(34):4275–80. doi:10.1016/j.vaccine.2014.06.028. PubMed DOI

David MP, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, Van Damme P. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol. 2009;115(3 Suppl):S1–6. doi:10.1016/j.ygyno.2009.01.011. PubMed DOI

Beck Y, Fritz R, Orlinger K, Kiermayr S, Ilk R, Portsmouth D, Pollabauer EM, Low-Baselli A, Hessel A, Kolch D, et al. Molecular basis of the divergent immunogenicity of two pediatric tick-borne encephalitis virus vaccines. J Virol. 2016;90(4):1964–72. doi:10.1128/JVI.02985-15. PubMed DOI PMC

Wittermann C, Schondorf I, Gniel D. Antibody response following administration of two paediatric tick-borne encephalitis vaccines using two different vaccination schedules. Vaccine. 2009;27(10):1661–66. doi:10.1016/j.vaccine.2008.10.003. PubMed DOI

Pollabauer EM, Pavlova BG, Low-Baselli A, Fritsch S, Prymula R, Angermayr R, Draxler W, Firth C, Bosman J, Valenta B, et al. Comparison of immunogenicity and safety between two paediatric TBE vaccines. Vaccine. 2010;28(29):4680–85. doi:10.1016/j.vaccine.2010.04.047. PubMed DOI

Prymula R, Pollabauer EM, Pavlova BG, Low-Baselli A, Fritsch S, Angermayr R, Geisberger A, Barrett PN, Ehrlich HJ. Antibody persistence after two vaccinations with either FSME-IMMUN® Junior or Encepur® children followed by third vaccination with FSME-IMMUN® Junior. Hum Vaccin Immunother. 2012;8(6):736–42. doi:10.4161/hv.20058. PubMed DOI

Klockmann U, Krivanec K, Stephenson JR, Hilfenhaus J. Protection against european isolates of tick-borne encephalitis virus after vaccination with a new tick-borne encephalitis vaccine. Vaccine. 1991;9(3):210–12. doi:10.1016/0264-410X(91)90157-2. PubMed DOI

Domnich A, Panatto D, Arbuzova EK, Signori A, Avio U, Gasparini R, Amicizia D. Immunogenicity against far eastern and siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: systematic review and meta-analysis. Hum Vaccin Immunother. 2014;10(10):2819–33. doi:10.4161/hv.29984. PubMed DOI PMC

Andersson CR, Vene S, Insulander M, Lindquist L, Lundkvist A, Gunther G. Vaccine failures after active immunisation against tick-borne encephalitis. Vaccine. 2010;28(16):2827–31. doi:10.1016/j.vaccine.2010.02.001. PubMed DOI

World Health Organization . Vaccines against tick-borne encephalitis: who position paper. Weekly Epidemiol Rec. 2011;86(24):241–56. PubMed

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...